Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-119100
Filing Date
2024-10-30
Accepted
2024-10-30 17:03:26
Documents
54
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q lrmr-20240930.htm   iXBRL 10-Q 1542296
2 EX-31.1 lrmr-ex31_1.htm EX-31.1 10913
3 EX-31.2 lrmr-ex31_2.htm EX-31.2 11009
4 EX-32.1 lrmr-ex32_1.htm EX-32.1 16423
  Complete submission text file 0000950170-24-119100.txt   6841705

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20240930.xsd EX-101.SCH 949005
57 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20240930_htm.xml XML 1214730
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36510 | Film No.: 241411289
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)